To date, only few studies have analyzed the PD-L1 expression in CTCs of patients diagnosed with breast cancer, NSCLC, head/neck cancer, prostate and bladder cancer and melanoma [16,17,18,19,20,21]. This evidence concerns the gene CD274 and urinary bladder carcinoma.